Lyell Immunopharma, Inc..
LYEL.US | Research and experimental development on natural sciences and engineering
Lyell Immunopharma, Inc. is a biotechnology company focused on developing T-cell reprogramming therapies for solid tumors. The company is pioneering a novel approach to address the challenges of T cell exhaustion and tumor-mediated immune suppression. Lyell is working on technologies to reprogram T ...Show More
Better Health for All
0
No evidence available to assess Lyell Immunopharma, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
No evidence available to assess Lyell Immunopharma, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess Lyell Immunopharma, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No information regarding fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clauses in supplier contracts, materials risk index, or supplier diversity spend was found in the provided articles.
1
The company's Code of Business Conduct and Ethics and Anti-Corruption Policy are mentioned, but there is no evidence that these apply to or are enforced within supplier contracts.
2
Honest & Fair Business
-20
Lyell Immunopharma, Inc. has a Whistleblower and Complaint Policy, which applies to all directors, officers, and employees.
1
It provides multiple reporting mechanisms, including a toll-free hotline and a website, and explicitly states a policy against retaliation for reporting potential violations.
2
The company's Corporate Governance Guidelines, last amended in December 2025, mandate that the Board be composed of a majority of independent directors.
3
The Audit Committee and Compensation Committee members are subject to additional independence requirements, and the Audit Committee reviews and approves related-person transactions.
4
Lyell also has an anti-corruption policy, last amended in December 2025, which includes compliance with the U.S. Foreign Corrupt Practices Act (FCPA) and prohibits misleading statements.
5
Kind to Animals
0
No specific, quantifiable data was found in the provided articles for any of the 'Kind to Animals' KPIs. While the company's research involves preclinical tests, in vivo data, and xenograft tumor models, and states compliance with the United States Animal Welfare Act, these facts do not provide the specific metrics required to score KPIs such as animal testing volume, the extent of alternative testing usage, or the details of an animal testing policy.
1
Information regarding cruelty-free certifications, humane certifications for operations, wildlife conservation impact, ethical input substitution, supplier audits for animal welfare, cage-free sourcing, R&D investment in animal-free technologies, animal agriculture ethics, animal-free R&D collaboration, or public policy engagement on animal welfare was not explicitly stated or quantified.
2
No War, No Weapons
0
No article content was provided, therefore no data could be extracted to assess Lyell Immunopharma, Inc. against the 'No War, No Weapons' ethical value.
1
No quantitative data, regulatory actions, certifications, awards, comparisons, contradictions, or data gaps were available for any of the KPIs.
2
Planet-Friendly Business
-20
Lyell Immunopharma, Inc. has 78% of its buildings green certified.
1
The company reported a 15.6% reduction in plastic waste, from 4,372 kg in 2022 to 3,692 kg in 2023.
2
For other waste streams in 2023, 45% of biological waste (6,500 kg) was recycled, and 23% of chemical waste (3,200 kg) was recycled.
3
The Nominating and Corporate Governance Committee reviews and discusses the company’s programs, policies, and risks related to environmental and sustainability matters.
4
The company's Code of Business Conduct and Ethics states a policy to conduct business in an environmentally responsible way, minimizing environmental impacts, reducing waste generation, and disposing of waste through safe and responsible methods.
5
Respect for Cultures & Communities
0
Lyell Immunopharma states that Free, Prior, and Informed Consent (FPIC) processes are not applicable to its operations.
1
Safe & Smart Tech
0
Lyell Immunopharma reports no material data breaches, violations, or unauthorized uses of IT systems or data that resulted in material cost, liability, or required notification.
1
The company states it is in material compliance with all applicable data privacy and security laws and regulations, including HIPAA, and has publicly posted policies for data privacy and security.
2
The Audit Committee, which meets at least quarterly, oversees risks related to data privacy, technology, information security, and cybersecurity.
3
The company's risk management processes include monitoring threats, conducting vulnerability assessments and penetration testing, and implementing measures like encryption, network security, and access controls.
4
They also use third parties to assist in identifying, assessing, and managing cybersecurity risks.
5
Lyell Immunopharma utilizes Fidelis CloudPassage Halo, integrated into its automated CICD and SDLC processes.
6
The company's Code of Business Conduct and Ethics, last amended December 3, 2025, includes policies on regulatory compliance, prohibiting unauthorized sharing of confidential information, and requiring employees to report suspicious activity.
7
The Code also states that Lyell complies with all laws and regulations regarding record preservation.
8
Employee security training is conducted by the Compliance Officer for new employees and as refreshers.
9
Zero Waste & Sustainable Products
-30
Lyell Immunopharma reduced its plastic waste by 15.6% from 4,372 kg in 2022 to 3,692 kg in 2023.
1
The company also reported a 92% management rate for biohazard waste.
2